# Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

> **NCT00457015** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 96 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** ecallantide
- **DRUG:** Phosphate Buffer Saline (PBS), pH 7.0

## Key facts

- **NCT ID:** NCT00457015
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-01
- **Primary completion:** 2008-06-01
- **Final completion:** 2008-06-01
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457015, "Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00457015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*